Testing a New Weight-Loss Medicine for Sleep Apnea
Treatments studied
Part of Brain & nervous system, Hormones & metabolism, Lungs & breathing clinical trials.
This study tests whether a new injectable medicine called NNC0487-0111 helps people with excess weight and moderate-to-severe obstructive sleep apnea (a condition where breathing stops repeatedly during sleep) lose weight and improve their sleep apnea—without needing a CPAP machine. The goal is to see if better weight loss can reduce sleep apnea symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older
- You have been diagnosed with moderate-to-severe obstructive sleep apnea (confirmed by a sleep test) and are not using a CPAP or similar airway pressure device
- You do not have diabetes or a blood sugar level (HbA1c) of 6.5% or higher
- You have not had sleep apnea-related surgery (like throat or nose surgery) in the past 3 months
- You are not currently taking or have never taken GLP-1 medicines like semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), or similar weight-loss or diabetes medications
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage study tests a new experimental medicine (NNC0113-5840) to see how it works in people who are overweight or have obesity. Researchers want to understand how the body processes this medicine and whether it's safe before testing it more widely.
This study tests a new injectable medicine (NNC0487-0111) to help people lose weight and improve obstructive sleep apnea (a breathing condition during sleep). You must already be using a CPAP machine (positive airway pressure device) for your sleep apnea.
This study tests an investigational medicine given as an injection to help people with obstructive sleep apnea and a high body mass index (BMI). It may reduce breathing pauses during sleep and support weight loss, all while you continue using your CPAP machine.
This trial tests an investigational drug called XW003 to see if it helps people with obesity and obstructive sleep apnea who are already using a positive airway pressure (PAP) machine, like CPAP. It aims to improve weight loss and sleep apnea symptoms.
This trial tests an investigational weekly injection called XW003 for weight loss in people who have obesity and moderate-to-severe sleep apnea but do not use a CPAP machine. It aims to see if the drug can help with weight loss and improve sleep apnea without the need for a breathing machine.
This study tests an investigational medication called eloralintide to see if it can improve sleep apnea in people who are overweight or have obesity. You will receive either the study drug or a placebo (inactive shot), and your sleep and weight will be monitored over time.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.